Clinical Trial

T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma

Name: T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma — clinical trial record (NCT06783270)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CRISPR-TIL

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this study is to assess wether it is safe and feasible to treat patients with tumor infiltrating lymphocytes that have been silenced for PD-1, using CRISPR-Cas9.

Trial Details

NCT Number	NCT06783270
Lead Sponsor	Inge Marie Svane
Conditions	Melanoma Metastatic
Enrollment	10 participants
Start Date	2024-12-16
Primary Completion	2027-01-01 (estimated)
Study Completion	2028-01-01 (estimated)
Updated on ClinicalTrials.gov	2025-01-20